Serum Irisin in Myocardial Infraction and Following Percutaneous Coronary Intevention

Study Overview
=================
Brief Summary
-----------------
The investigators aim to evaluate circulating irisin levels alterations in patients with acute myocardial infraction and in patients with coronary artery disease subjected to percutaneous coronary intervention.

Detailed Description
-----------------
Irisin is a newly discovered myokine induced in exercise. There is evidence that cardiac muscle produces more irisin than skeletal muscle in response to exercise. Furthermore, irisin has been associated with isoproterenol-induced myocardial infarction (MI) in rats while it has been reported to decrease after acute myocardial infarction in humans. The investigators aim 1) to investigate circulating irisin levels in patients at the time of acute myocardial infarction and after reprefusion [primary percutaneous coronary intervention (PCI)] 2) to compare irisin' s diagnostic and prognostic value and specificity value in myocardial infarction with known markers of cardiac injury such as creatine kinase-MB isoenzyme (CK-MB) and troponin 3) to evaluate irisin as an early necrosis biomarker 4) To evaluate irisin's sensitivity as a biomarker to detect minor myocardial necrosis after elective percutaneous coronary intervention

Official Title
-----------------
Serum Irisin Levels in Myocardial Infraction and Following Percutaneous Coronary Intevention

Conditions
-----------------
Myocardial Infarction, Coronary Artery Disease

Intervention / Treatment
-----------------
* Procedure: percutaneous coronary intervention
* Procedure: coronary angiography
* Device: Stent, Medronic Resolute Integrity


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with acute myocardial infraction (MI) or with coronary artery disease without myocardial infraction who need percutaneous coronary intervention Exclusion Criteria: age < 20 years old diseases or medications that could affect cardiac muscle or skeletal muscle metabolism musculoskeletal injury of surgery 6 months prior to recruitment severe liver or kidney disease (creatinine clearance < 60ml/min/1.73m2) or liver or kidney transplantation

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: myocardial infraction<br>Patients with acute myocardial infraction who are admitted to the emergency department of 424 General Military Hospital before and after percutaneous coronary intervention and stent placement | Procedure: percutaneous coronary intervention<br>* a non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease<br>* Other names: coronary angioplasty;Procedure: coronary angiography<br>* is a procedure performed along with cardiac catheterization that uses X-ray imaging to see your heart's blood vessels<br>Device: Stent, Medronic Resolute Integrity<br>* A stent is placed in an artery as part of a procedure called percutaneous coronary intervention (PCI) to restore blood flow through narrow or blocked arteries. A stent helps support the inner wall of the artery in the months or years after PCI.<br>|
| Active Comparator: coronary artery disease<br>Patients with coronary artery disease but not myocardial infraction who are being subjected to coronary angiography and percutaneous coronary intervention and stent placement | Procedure: percutaneous coronary intervention<br>* a non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease<br>* Other names: coronary angioplasty;Procedure: coronary angiography<br>* is a procedure performed along with cardiac catheterization that uses X-ray imaging to see your heart's blood vessels<br>Device: Stent, Medronic Resolute Integrity<br>* A stent is placed in an artery as part of a procedure called percutaneous coronary intervention (PCI) to restore blood flow through narrow or blocked arteries. A stent helps support the inner wall of the artery in the months or years after PCI.<br>|
| Active Comparator: Control<br>Patients subjected to coronary angiography and found with no presence of coronary artery disease | Procedure: coronary angiography<br>* is a procedure performed along with cardiac catheterization that uses X-ray imaging to see your heart's blood vessels<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| changes from baseline in serum irisin measured by ELISA |  | baseline and 6 hours or 24 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| changes from baseline in troponin |  | baseline and 6 hours or 24 hours | 
| changes from baseline in serum lactate dehydrogenase |  | baseline and 6 hours or 24 hours | 
| changes from baseline in serum creatine kinase |  | baseline and 6 hours or 24 hours | 
| changes from baseline in serum creatine kinase-MB isoenzyme |  | baseline and 6 hours or 24 hours | 
| changes from baseline in serum follistatin |  | baseline and 6 hours or 24 hours | 
| changes from baseline in serum follistatin-like protein 3 (FSTL-3) |  | baseline and 6 hours or 24 hours | 
| changes from baseline in serum Activin A |  | baseline and 6 hours or 24 hours | 
| changes from baseline in serum Activin B |  | baseline and 6 hours or 24 hours | 
| changes from baseline in serum insulin growth factor 1 (IGF1) |  | baseline and 6 hours or 24 hours | 
| changes from baseline in serum insulin growth factor binding protein 3 (IGFBP3) |  | baseline and 6 hours or 24 hours | 
| changes from baseline in serum insulin growth factor binding protein 4 (IGFBP4) |  | baseline and 6 hours or 24 hours | 
| changes from baseline in serum pico pregnancy-associated plasma protein A (PAPP-A) |  | baseline and 6 hours or 24 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
irisin, myocardial infarction, coronary